Breast CancerARRESTNCT00246961
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
An observational study of Breast Cancer, run by AstraZeneca at 33 sites in Netherlands.
Trial summary
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer
- How many people
- 200 participants
- Where
- 33 sitesNetherlands
- Study dates
- Jul 2004to not given
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Postmenopausal
- Hormone sensitive breast cancer
- Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago
Who cannot join
- Visceral metastases
- Patients with signs of progression at the moment of changing therapy
- Patients who have used other endocrine treatments for breast cancer besides tamoxifen
Trial locations and contacts
33 sites in 1 country.
33 sites in 1 country
Netherlands33 sites
Research Site
's-Hertogenbosch
Research Site
Alkmaar
Research Site
Antwerpen
Research Site
Apeldoorn
Research Site
Bergen op Zoom
Research Site
Boxmeer
Research Site
Breda
Research Site
Doetinchem
Research SIte
Dordrecht
Research Site
Ede
Research Site
Eindhoven
Research Site
Enschede
Research Site
Flushing
Research Site
Geldrop
Research Site
Groningen
Research Site
Harderwijk
Research Site
Helmond
Research Site
Hoogeveen
Research Site
Hoorn
Research Site
Leiden
Research Site
Oosterhout
Research Site
Purmerend
Research Site
Roermond
Research Site
Roosendaal
Research Site
Rotterdam
Research Site
Schiedam
Research Site
Terneuzen
Research Site
The Hague
Research Site
Tiel
Research Site
Venray
Research Site
Winterswijk
Research Site
Zoetermeer
Research Site
Zutphen
About this study
Official title: Arimidex: Reason for and Effect of Change From Tamoxifen
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.
- Conditions
- Breast Cancer
- Keywords
- Adjuvant
- Medical subject headings
- Breast Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2005 (estimated)
- Study startJul 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 200 participants
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- AstraZeneca The Netherlands Medical Director, MD, Study director, AstraZeneca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00246961
- Sponsor's protocol ID
- D5392NL0002
- Other IDs
- ARREST
- Acronym
- ARREST
- Status last verified
- Jun 2007
- First submitted
- 31 Oct 2005
- Last updated
- 12 Oct 2007
- Results posted
- No
- Data monitoring committee
- No